Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3209590 Steady-State PK/PD Clamp Study in T2DM
NCT06169982Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Area under the concentration curve at steady state. Started Dec 2023; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06169982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169982.